Current status and progress of the development of prostate cancer vaccines

Citations Over TimeTop 12% of 2023 papers

Abstract

At present, common treatments of prostate cancer mainly include surgery, radiotherapy, chemotherapy and hormone therapy. However, patients have high recurrence rate after treatment, and are prone to castration-resistant prostate cancer. Tumor vaccine is based on tumor specific antigen (TSA) and tumor associated antigen (TAA) to activate specific immune response of the body to cancer cells. With continuous maturity of tumor vaccine technology, different forms of prostate cancer vaccines have been developed, such as cellular vaccines, extracellular-based anti-tumor vaccines, polypeptide vaccines, and nucleic acid vaccines. In this review, we summarize current status and progress in the development of prostate cancer vaccines.

Related Papers

• → Influenza vaccination responses: Evaluating impact of repeat vaccination among health care workers(2017)37 cited
• → Comparison of primary vaccination regimes for equine influenza: Working towards an evidence‐based regime(2013)26 cited
• → Is annual vaccination best? A modelling study of influenza vaccination strategies in children(2022)6 cited
• → Studies of putative B2-microglobulins in the chicken ((1986)
• → The Impact of Vaccination And Patient Characteristics on Influenza Vaccination Uptake(2017)